可能因为您的浏览器不支持样式,您可以更新您的浏览器到最新版本,以获取对此功能的支持,访问下面的网站,获取关于浏览器的信息:
[1] 陈在嘉,高润林. 冠心病[M]. 北京: 人民卫生出版社, 2002:919-929.
[2] Calvillo L, Latini R, Kajstura J, et al. Recombinant human erythropoietin protects the myocardium from ischemiareperfusion injury and promotes beneficial remodeling[J]. Proc Natl Acad Sci USA, 2003, 100(8):4802-4806.
[3] Cai Z, Manalo DJ, Wei G, et al. Hearts from redents exposed to intermittent hypoxia or erythropoietin are protected against ischemiareperfusion injure[J]. Circulation, 2003, 108(1):79-85.
[4] Sobel BE, Bresnahan GF, Shell WE, et al. Estimation of infarction size in man and its relation on prognosis[J]. Circulation, 1972, 46(4):640-648.
[5]Barosi G. Inadequate erythropoietin response to anemia:definition and clinical relevance[J]. Ann Hematol, 1994, 68(5):215-223.
[6] Tanabe N, Ohnishi K, Fukui H, et al. Effect of smoking on the serum concentratin of erythropoietin and granulocyteclolony stimulating factor[J]. Intern Med, 1997, 36(10):680-684.
[7] Bullard AJ, Yellon DM. Chronic erythropoietin treatment limits infarctsize in the myocardium in vitro[J]. Cardiovasc Drugs Ther, 2005, 19(5):333-336.
[8] Heeschen C, Aicher A, Lehmann R, et al. Erythropoietin is a potent physiological stimulus for endothelial progenitor cell mobilization[J]. Blood, 2003, 102(4):1340-1346.